Mangoceuticals, Inc.

NasdaqCM MGRX

Mangoceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

Mangoceuticals, Inc. Debt to Equity Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqCM: MGRX

Mangoceuticals, Inc.

CEO	Mr. Jacob D. Cohen
IPO Date	March 21, 2023
Location	United States
Headquarters	15110 North Dallas Parkway
Employees	3
Sector	Health Care
Industries Telehealth Pharmaceuticals

Description

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Key trends

Past 5 years